

WEST**End of Result Set**☐ **Generate Collection** **Print**

L1: Entry 1 of 1

File: USPT

Aug 14, 2001

US-PAT-NO: 6274143

DOCUMENT-IDENTIFIER: US 6274143 B1

TITLE: Methods of delaying development of HMFG-associated tumors using anti-idiotypic antibody 11D10

DATE-ISSUED: August 14, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chatterjee; Malaya	Lexington	KY	40502	
Foon; Kenneth A.	Lexington	KY	40536	

US-CL-CURRENT: 424/155.1; 424/131.1, 424/138.1, 424/139.1, 424/143.1, 424/156.1,
424/174.1, 530/387.2

CLAIMS:

What is claimed is:

1. A method of delaying development of a human milk fat globule (HMFG)-associated tumor in an individual having a low tumor burden of an HMFG-associated tumor, comprising administering to the individual an amount of anti-idiotypic antibody 11D10 sufficient to delay development of said HMFG-associated tumor, wherein 11D10 is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC) as Accession No. HB 12020, or progeny thereof, whereby development of said HMFG-associated tumor is delayed.
2. The method of claim 1, wherein the individual is high risk of development of an HMFG-associated tumor.
3. The method of claim 2, wherein the individual is in an adjuvant setting.
4. The method of claim 1, wherein 11D10 is administered with an adjuvant.
5. The method of claim 4, wherein the adjuvant is aluminum hydroxide.
6. The method of claim 1, wherein the HMFG-associated tumor is a breast tumor.
7. The method of claim 1, wherein 11D10 is administered in an amount of about 1 mg to about 4 mg.
8. The method of claim 1, wherein 11D10 is administered in an amount of about 2 mg.
9. The method of claim 1, wherein 11D10 is administered at weekly intervals.
10. The method of claim 1, wherein 11D10 is administered every two weeks.
11. The method of claim 1, wherein 11D10 is heat-treated prior to administration.
12. A method of treatment of a human milk fat globule (HMFG)-associated tumor in

an individual with a low tumor burden of an HMFG-associated tumor, comprising administering to the individual an amount of anti-idiotypic antibody 11D10 sufficient to treat said HMFG-associated tumor, wherein 11D10 is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC) as Accession No. HB 12020, or progeny thereof, whereby said HMFG-associated tumor is treated.

13. The method of claim 12, wherein the individual is high risk of development of an HMFG-associated tumor.

14. The method of claim 13, wherein the individual is in an adjuvant setting.

15. The method of claim 12, wherein 11D10 is administered with an adjuvant.

16. The method of claim 15, wherein the adjuvant is aluminum hydroxide.

17. The method of claim 12, wherein the HMFG-associated tumor is a breast tumor.

18. The method of claim 12, wherein 11D10 is administered in an amount of about 1 mg to about 4 mg.

19. The method of claim 12, wherein 11D10 is administered in an amount of about 2 mg.

20. The method of claim 12, wherein 11D10 is administered at weekly intervals.

21. The method of claim 12, wherein 11D10 is administered every two weeks.

22. The method of claim 12, wherein 11D10 is heat-treated prior to administration.

23. The method of claim 1, wherein the antibody has light and heavy chain variable region amino acid sequences in SEQ ID NO:2 and SEQ ID NO:4, respectively.

24. The method of claim 12, wherein the antibody has light and heavy chain variable region amino acid sequences in SEQ ID NO:2 and SEQ ID NO:4, respectively.